2 results
Approved WMOCompleted
The primary objective of this phase III study is to demonstrate that lixisenatide can reduce cardiovascularmorbidity and mortality (composite endpoint of cardiovascular (CV) death, non-fatal myocardialinfarction (MI), non-fatal stroke,…
Approved WMOCompleted
To measure the effectiveness of intrathecal methylprednisolone and lidocaine on reducing PHN. Measurement of mthylprednisolone concentrations in cerebrospinal fluid (Part I only).